Implementation of a closed system transfer device in oncology units

0

The objective of this study was to evaluate the effect of CSTD implementation on central line-associated bloodstream infection (CLABSI) rates” Fox et al (2018).

Background:

In February 2016 the United States Pharmacopeia introduced general chapter 800 requiring the use of closed system transfer devices (CSTD) for preparation and administration of antineoplastic hazardous drugs. The objective of this study was to evaluate the effect of CSTD implementation on central line-associated bloodstream infection (CLABSI) rates.



Reference:

Fox, J., Rensing, K., Rumsey, A., Grimes, L., Rojek, R., Dubberke, E., Warren, D. and Mayfield, J. (2018) The Impact on Central Line-Associated Bloodstream Infection Rates Following the Introduction of a Closed System Transfer Device in Oncology Units. American Journal of Infection Control. 46(6, Supplement), p.S64-S65.

DOI: https://doi.org/10.1016/j.ajic.2018.04.127

Share.

Comments are closed.